These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 16433192)

  • 41. Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and beta-lactams tested against gram-negative bacilli.
    Sader HS; Huynh HK; Jones RN
    Diagn Microbiol Infect Dis; 2003 Nov; 47(3):547-50. PubMed ID: 14596974
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activity of levofloxacin and ciprofloxacin in combination with cefepime, ceftazidime, imipenem, piperacillin-tazobactam and amikacin against different Pseudomonas aeruginosa phenotypes and Acinetobacter spp.
    Drago L; De Vecchi E; Nicola L; Colombo A; Guerra A; Gismondo MR
    Chemotherapy; 2004 Oct; 50(4):202-10. PubMed ID: 15452399
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
    J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro activity of beta-lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginosa.
    Song W; Woo HJ; Kim JS; Lee KM
    Int J Antimicrob Agents; 2003 Jan; 21(1):8-12. PubMed ID: 12507832
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bactericidal in-vitro activity of beta-lactams and beta-lactamase inhibitors, alone or associated, against clinical strains of Acinetobacter baumannii: effect of combination with aminoglycosides.
    Joly-Guillou ML; Decré D; Herrman JL; Bourdelier E; Bergogne-Bérézin E
    J Antimicrob Chemother; 1995 Oct; 36(4):619-29. PubMed ID: 8591936
    [TBL] [Abstract][Full Text] [Related]  

  • 46.
    Moya B; Barcelo IM; Cabot G; Torrens G; Palwe S; Joshi P; Umarkar K; Takalkar S; Periasamy H; Bhagwat S; Patel M; Bou G; Oliver A
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782985
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of different methods for determining beta-lactam susceptibility in Pseudomonas aeruginosa.
    Sapino B; Mazzuccato S; Solinas M; Gion M; Grandesso S
    New Microbiol; 2012 Oct; 35(4):491-4. PubMed ID: 23109018
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative activity of beta-lactam agents (carbapenem excepted) against Pseudomonas aeruginosa strains with CARB or OXA beta-lactamases.
    Bert F; Branger C; Lambert-Zechovsky N
    Chemotherapy; 2004 Apr; 50(1):31-4. PubMed ID: 15084803
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Evolution of susceptibility to antibiotics of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumanii, in a University Hospital Center of Beirut between 2005 and 2009].
    Hamouche E; Sarkis DK
    Pathol Biol (Paris); 2012 Jun; 60(3):e15-20. PubMed ID: 21719212
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro synergy of ceftolozane/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa.
    Cuba GT; Rocha-Santos G; Cayô R; Streling AP; Nodari CS; Gales AC; Pignatari ACC; Nicolau DP; Kiffer CRV
    J Antimicrob Chemother; 2020 Jul; 75(7):1874-1878. PubMed ID: 32240299
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro synergy of ticarcillin/clavulanate in combination with aztreonam and ceftolozane/tazobactam against SPM-1-producing Pseudomonas aeruginosa strains.
    Rocha-Santos G; Cuba GT; Cayô R; Streling AP; Nodari CS; Gales AC; Pignatari ACC; Nicolau DP; Kiffer CRV
    Diagn Microbiol Infect Dis; 2021 Jun; 100(2):115343. PubMed ID: 33652305
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of antimicrobial susceptibility for β-lactams against clinical isolates from 51 medical centers in Japan (2008).
    Ishii Y; Ueda C; Kouyama Y; Tateda K; Yamaguchi K
    Diagn Microbiol Infect Dis; 2011 Apr; 69(4):443-8. PubMed ID: 21396543
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of ertapenem use on Pseudomonas aeruginosa and Acinetobacter baumannii imipenem susceptibility rates: collateral damage or positive effect on hospital ecology?
    Sousa D; Castelo-Corral L; Gutiérrez-Urbón JM; Molina F; López-Calviño B; Bou G; Llinares P
    J Antimicrob Chemother; 2013 Aug; 68(8):1917-25. PubMed ID: 23557925
    [TBL] [Abstract][Full Text] [Related]  

  • 54. WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.
    Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289035
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Convenient test using a combination of chelating agents for detection of metallo-beta-lactamases in the clinical laboratory.
    Kim SY; Hong SG; Moland ES; Thomson KS
    J Clin Microbiol; 2007 Sep; 45(9):2798-801. PubMed ID: 17596358
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Annual trends in antibiotic resistance of nosocomial Acinetobacter baumannii strains and the effect of synergistic antibiotic combinations.
    Tatman-Otkun M; Gürcan S; Ozer B; Shokrylanbaran N
    New Microbiol; 2004 Jan; 27(1):21-8. PubMed ID: 14964402
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Pseudomonas aeruginosa: bactericidal activity on various beta-lactam resistance phenotypes of 8 antibiotics and 7 combinations].
    Dubrous P; Cavallo JD; Hernandez E; Nordmann P; Fabre R
    Pathol Biol (Paris); 1997 May; 45(5):433-7. PubMed ID: 9296099
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synergic in-vitro activity of imipenem and sulbactam against Acinetobacter baumannii.
    Choi JY; Park YS; Cho CH; Park YS; Shin SY; Song YG; Yong D; Lee K; Kim JM
    Clin Microbiol Infect; 2004 Dec; 10(12):1098-101. PubMed ID: 15606639
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
    Page MG; Dantier C; Desarbre E
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2291-302. PubMed ID: 20308379
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
    Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
    Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.